Published in Adv Clin Exp Med on January 16, 2014
Serum Adiponectin and Leptin Concentrations in Relation to Body Fat Distribution, Hematological Indices and Lipid Profile in Humans. Int J Environ Res Public Health (2015) 0.79
T, B, and NKT Cells in Systemic Inflammation in Obstructive Sleep Apnoea. Mediators Inflamm (2015) 0.76
Is C-reactive protein a marker of obstructive sleep apnea?: A meta-analysis. Medicine (Baltimore) (2017) 0.75
High-frequency gamma oscillations and human brain mapping with electrocorticography. Prog Brain Res (2006) 2.85
Cortical γ responses: searching high and low. Int J Psychophysiol (2010) 1.38
Quantifying auditory event-related responses in multichannel human intracranial recordings. Front Comput Neurosci (2010) 0.97
Comparison of cytokeratin 19 expression in tumor tissue and serum CYFRA 21-1 levels in non-small cell lung cancer. Pol Arch Med Wewn (2009) 0.97
CTLA-4, CD28, and ICOS gene polymorphism associations with non-small-cell lung cancer. Hum Immunol (2011) 0.91
Antibiotic resistant Escherichia coli in hospital and municipal sewage and their emission to the environment. Ecotoxicol Environ Saf (2013) 0.87
Fucosylation of serum glycoproteins in lung cancer patients. Clin Chem Lab Med (2005) 0.87
[Alveolar proteinosis after professional exposure to cotton and linen dust, successfully treated with whole lung lavage--a case report]. Pneumonol Alergol Pol (2004) 0.87
Galectin-3 and cyclin D1 expression in non-small cell lung cancer. J Exp Clin Cancer Res (2011) 0.86
Does the KIR2DS5 gene protect from some human diseases? PLoS One (2010) 0.86
Metallothionein 1F and 2A overexpression predicts poor outcome of non-small cell lung cancer patients. Exp Mol Pathol (2012) 0.85
Correlation between expression of metallothionein and expression of Ki-67 and MCM-2 proliferation markers in non-small cell lung cancer. Anticancer Res (2011) 0.85
Expression of metallothionein-III in patients with non-small cell lung cancer. Anticancer Res (2013) 0.84
Apoptotic regulators: P53 and survivin expression in non-small cell lung cancer. Cancer Genomics Proteomics (2010) 0.84
KIR2DL2/S2 and HLA-C C1C1 genotype is associated with better response to treatment and prolonged survival of patients with non-small cell lung cancer in a Polish Caucasian population. Hum Immunol (2012) 0.84
Comparison of haptoglobin and alpha₁-acid glycoprotein glycosylation in the sera of small cell and non-small cell lung cancer patients. Postepy Hig Med Dosw (Online) (2013) 0.83
Laryngeal tuberculosis. Lancet Infect Dis (2004) 0.82
Impaired zeta chain expression and IFN-gamma production in peripheral blood T and NK cells of patients with advanced lung cancer. Oncol Rep (2009) 0.82
[Combined pulmonary fibrosis and emphysema - case report and literature review]. Pneumonol Alergol Pol (2009) 0.82
Proceedings of the Second International Workshop on Advances in Electrocorticography. Epilepsy Behav (2011) 0.82
Role of lymphangiogenesis in lung cancer. Folia Histochem Cytobiol (2009) 0.81
[Leptin serum levels in cachectic and non-cachectic lung cancer patients]. Pneumonol Alergol Pol (2009) 0.80
[The prognostic value of cytokeratin 19 expression in non-small cell lung cancer]. Pneumonol Alergol Pol (2007) 0.80
Apoptotic markers p53, Bcl-2 and Bax in primary lung cancer. In Vivo (2006) 0.80
[Comparative evaluation of two health-related quality of life questionnaires in patients with sleep apnea]. Wiad Lek (2004) 0.79
Quinazolinone fungal efflux pump inhibitors. Part 2: In vitro structure-activity relationships of (N-methyl-piperazinyl)-containing derivatives. Bioorg Med Chem Lett (2004) 0.79
Cyclin A and Cyclin E expression in resected non-small cell lung cancer stage I-IIIA. In Vivo (2009) 0.78
Stilbene analogs as inducers of apolipoprotein-I transcription. Eur J Med Chem (2010) 0.78
[Expression of p53, bcl-2 and nm23 proteins in squamous cell lung cancer]. Pneumonol Alergol Pol (2009) 0.78
[Serum chitotriosidase activity as a biomarker of pulmonary sarcoidosis]. Pol Merkur Lekarski (2011) 0.77
[Suppression of chronic nocturnal cough during continuous positive airway pressure (CPAP) treatment in a patient with asthma and obstructive sleep apnea syndrome]. Pneumonol Alergol Pol (2011) 0.77
Presence of high-molecular-weight forms and domain alterations of fibronectin in pleural effusion of patients with lung cancer. Clin Biochem (2009) 0.77
[The evaluation of prognostic value of cyclin B1 expression in patients with resected non-small-cell lung cancer stage I-IIIA--preliminary report]. Pol Merkur Lekarski (2010) 0.77
[The most common infections of lung allografts]. Pneumonol Alergol Pol (2009) 0.77
[Assessment of sociodemographic and nutritional status of lung cancer patients]. Rocz Panstw Zakl Hig (2011) 0.77
[The epidemiology of lung cancer]. Pneumonol Alergol Pol (2007) 0.77
A study of the dynamics of seizure propagation across micro domains in the vicinity of the seizure onset zone. J Neural Eng (2015) 0.77
[Tuberculosis after renal transplantation]. Pneumonol Alergol Pol (2009) 0.77
[Serum activity of chitotriosidase, lysozyme and cathepsin H in patients with lung cancer and patients with inflammatory exudate (preliminary report)]. Pol Merkur Lekarski (2009) 0.76
Serum levels of apoptosis-related markers (sFasL, TNF-a, p53 and bcl-2) in COPD patients. Pneumonol Alergol Pol (2015) 0.76
[Concentrations of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinases-1 in serum of patients with chronic obstructive pulmonary disease]. Pol Merkur Lekarski (2011) 0.76
[A case of kappa L-chain primary nodular lung amyloidosis]. Pol Merkur Lekarski (2008) 0.75
[Small-cell lung cancer diagnostic and therapeutic recommendations of Polish Lung Cancer Group]. Pneumonol Alergol Pol (2007) 0.75
Pulmonary function impairment in patients undergoing allogeneic hematopoietic cell transplantation. Adv Exp Med Biol (2013) 0.75
209 Movement-Related Dynamics of Beta Band Causal Interactions Between Subthalamic Nucleus and Sensorimotor Cortex Revealed Through Intraoperative Recordings in Parkinson's Disease. Neurosurgery (2016) 0.75
[Neurosarcoidosis--case report]. Pol Merkur Lekarski (2014) 0.75
[The effect of inhaled low molecular weight heparin on cell composition in bronchoalveolar lavage fluid and serum levels of soluble receptor IL-2 in bronchial asthma patients]. Pol Merkur Lekarski (2002) 0.75
[Beta-blockers usage in cardio-vascular diseases co-existing with COPD]. Pol Merkur Lekarski (2012) 0.75
[VEGF in the cancer anorexia-cachexia syndrome in patients with lung cancer]. Pneumonol Alergol Pol (2006) 0.75
[Quality of life outcomes of pulmonary rehabilitation in patients with chronic obstructive pulmonary disease (COPD)]. Wiad Lek (2007) 0.75
[The incidence and pathogenesis of cancer anorexia-cachexia syndrome in lung cancer]. Pneumonol Alergol Pol (2008) 0.75
[Pulmonary hypertension and pulmonary embolism in chronic obstructive pulmonary disease]. Pol Merkur Lekarski (2009) 0.75
Hypoxemia during bilevel positive airway pressure treatment in patients with obstructive sleep apnea syndrome and chronic respiratory insufficiency. Adv Exp Med Biol (2013) 0.75
[Smoking cessation program based on pharmacological support (bupropion SR). Our own experience]. Pneumonol Alergol Pol (2003) 0.75
[Chronic obstructive pulmonary disease exacerbation--effects on quality of life]. Pol Arch Med Wewn (2005) 0.75
[Dietetic aspects of giving up smoking]. Wiad Lek (2010) 0.75
[Quality of life in patients with obstructive sleep apnea]. Pol Merkur Lekarski (2004) 0.75
[Serum and bronchoalveolar lavage fluid neopterin levels in patients with bronchial asthma]. Pol Merkur Lekarski (2003) 0.75
[The cyclin A, B1, D1 and E expression in advanced non-small cell lung cancer--stages IIIB-IV (preliminary report)]. Pol Merkur Lekarski (2011) 0.75
[Serum levels analysis of TGF-Beta and VEGF in patients with cancer anorexia-cachexia syndrome in lung cancer]. Wiad Lek (2007) 0.75
[Nutritional knowlegde and lifestyle of obese patients with diagnosed obturative sleep apnea]. Rocz Panstw Zakl Hig (2010) 0.75
[Application of metabolomic in COPD diagnosing]. Pol Merkur Lekarski (2012) 0.75
[Chronic obstructive pulmonary disease and cardiovascular diseases]. Pneumonol Alergol Pol (2010) 0.75
[Increase of skin reactivity to histamine in patients after lung cancer surgery]. Pneumonol Alergol Pol (2002) 0.75
[Diagnosis and treatment of tobacco dependence]. Pneumonol Alergol Pol (2005) 0.75
[Wegener's granulomatosis--a disease of many faces]. Pneumonol Alergol Pol (2002) 0.75
[Elastase and alpha-1 proteinase inhibitor complex in broncho-alveolar lavage fluid in patients with bronchial asthma and sarcoidosis]. Pol Merkur Lekarski (2003) 0.75
[Tumor markers TPA and Cyfra 21.1 in patients with non-small cell lung cancer after surgery and chemotherapy]. Pol Merkur Lekarski (2002) 0.75
Skin reactivity to histamine and expression of histamine receptors mRNA in lymphocytes of healthy subjects and non-small-cell lung cancer patients before and after surgery. Lung Cancer (2004) 0.75
[Phagocytosis and chemiluminescence of neutrophils in patients with pulmonary tuberculosis]. Pol Merkur Lekarski (2003) 0.75
[Treatment of nicotine dependence based on bupropion SR and educational support--one year observation and analysis of the reasons of relapses]. Pneumonol Alergol Pol (2004) 0.75
[Changes in the percentage of activated lymphocytes in bronchoalveolar lavage fluid in patients with clinical improvement of sarcoidosis]. Wiad Lek (2006) 0.75
[Coexistence of obstructive sleep apnea syndrome and chronic obstructive pulmonary disease]. Pneumonol Alergol Pol (2011) 0.75
The total synthesis of racemic teucvin and 12-epi-teucvin. Angew Chem Int Ed Engl (2003) 0.75
[Anticancer chemotherapy containing cisplatin in patients with lung cancer and kidney function]. Pol Arch Med Wewn (2002) 0.75
Spatial-temporal functional mapping of language at the bedside with electrocorticography. Neurology (2016) 0.75
[Cathepsin B activity and concentration of elastase and alpha-1 proteinase inhibitor complex in non-small-cell lung cancer: 2 year follow-up study]. Pol Merkur Lekarski (2003) 0.75